Location: Switzerland, Nidwalden, Stans
Employees: 11-50
Total raised: $3M
Founded date: 2015
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.04.2025 | - | $3M | - |
Mentions in press and media 23
| Date | Title | Description |
| 09.04.2025 | NLS Pharma raises $3 million equity funding | NLS Pharma IS a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, announced the closing of a $2 million equity financing of preferred shares at a stated va... |
| 05.02.2025 | NLS Pharma gets go-ahead for reverse merger | Swiss clinical-stage biopharmaceutical company NLS Pharmaceutics plans to merge with Kadimastem, a clinical-stage cell therapy company developing and manufacturing "off-the-shelf" allogeneic cell products for the treatment of neu... |
| 19.12.2022 | NLS Pharmaceutics sells shares for USD 10 million to BVF | |
| 26.04.2022 | NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering | ZURICH, SWITZERLAND / ACCESSWIRE / April 26, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development ... |
| 01.11.2021 | NLS Pharmaceutics CEO Issues Letter to Shareholders | STANS, SWITZERLAND / ACCESSWIRE / November 1, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development ... |
| 28.09.2021 | NLS Pharmaceutics : Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment | STANS, SWITZERLAND / ACCESSWIRE / September 28, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of in... |
| 08.09.2021 | NLS Pharmaceutics : to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference | STANS, SWITZERLAND / ACCESSWIRE / September 8, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of... |
| 19.08.2021 | NLS Pharmaceutics : Announces Notice of Allowance for U.S. Patent Application Covering its Proprietary Mazindol Formulation | STANS, SWITZERLAND / ACCESSWIRE / August 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of i... |
| 28.05.2021 | NLS Pharmaceutics to Present at The MicroCap Rodeo 2021 Summer Solstice: Best Ideas from the Buyside Conference on June 1 | |
| 18.05.2021 | NLS Pharmaceutics Announces New Study Data Confirming Mazindol's Unique Orexin Pathway Activation for Treating Narcolepsy |
Show more